Funding of Parkinson research from industry and US federal and foundation sources

Authors


  • The views expressed in the article reflect those of the authors alone and do not necessarily reflect those of any funding organization.

  • Potential conflict of interest: The Michael J. Fox Foundation supported this research. Drs. Frasier, Fiske, and Sherer, Co-authors of the manuscript, are employees of the Michael J. Fox Foundation. Dr. Dorsey holds stock options in Avid Radiopharmaceuticals, Inc., which had no role in this manuscript.

Abstract

Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies. © 2009 Movement Disorder Society

Ancillary